Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results – Nasdaq
Weekly Register |
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
Nasdaq As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Critical Comparison: Arena Pharmaceuticals (ARNA) & Editas Medicine (NASDAQ:EDIT) Financial Newsletter – Zacks |
